Department of Health and Human Services October 23, 2007 – Federal Register Recent Federal Regulation Documents

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting
Document Number: E7-20854
Type: Notice
Date: 2007-10-23
Agency: Food and Drug Administration, Department of Health and Human Services
Notice of Availability
Document Number: E7-20837
Type: Notice
Date: 2007-10-23
Agency: Aging Administration, Department of Health and Human Services
Availability of Draft Toxicological Profiles
Document Number: E7-20819
Type: Notice
Date: 2007-10-23
Agency: Agency for Toxic Substances and Disease Registry, Department of Health and Human Services
The Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA), as amended by the Superfund Amendments and Reauthorization Act of 1986 (SARA), section 104(i)(3) [42 U.S.C. 9604(i)(3)] directs the Administrator of ATSDR to prepare toxicological profiles of priority hazardous substances and to revise and publish each updated toxicological profile as necessary. This notice announces the availability of the 21st set of toxicological profiles, which consists of one new draft and six updated drafts, prepared by ATSDR for review and comment.
National Heart, Lung, and Blood Institute; Notice of Meeting
Document Number: 07-5252
Type: Notice
Date: 2007-10-23
Agency: Department of Health and Human Services, National Institutes of Health
Guidance for Industry, Food and Drug Administration, and Foreign Governments; Fiscal Year 2008 Medical Device User Fee Small Business Qualification and Certification; Availability
Document Number: 07-5226
Type: Notice
Date: 2007-10-23
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of the guidance entitled ``FY 2008 Medical Device User Fee Small Business Qualification and Certification.'' This guidance explains how a business headquartered in the United States or headquartered in a foreign nation may respectively qualify as ``small business'' under the medical device user fee provisions of the Federal Food, Drug, and Cosmetic Act (the act). A ``small business'' may pay certain medical device user fees at a substantial discount from the standard (full) fee rates and may obtain a one-time fee waiver for its first premarket application (a premarket approval application (PMA), biologics license application (BLA), product development protocol (PDP), or premarket report (PMR)).
Salt and Sodium; Petition to Revise the Regulatory Status of Salt and Establish Food Labeling Requirements Regarding Salt and Sodium; Public Hearing; Request for Comments
Document Number: 07-5216
Type: Proposed Rule
Date: 2007-10-23
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing a public hearing concerning FDA's policies regarding salt (sodium chloride) and sodium in food. FDA also is announcing the availability for comment of a citizen petition, submitted by the Center for Science in the Public Interest (CSPI), requesting that FDA make changes to the regulatory status of salt, require limits on salt in processed foods, and require health messages related to salt and sodium. The purpose of the hearing is for FDA to share its current framework of policies regarding salt and sodium and to solicit information and comments from interested persons on this current framework and on potential future approaches, including approaches described in the citizen petition.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.